Parker Institute for Cancer Immunotherapy
Marko Spasic, MD, serves as Senior Medical Director, Head of Medical and Scientific Partnerships at PICI. He works across mission-focused initiatives to realize the institute’s goal to turn cancer into a curable disease. Dr. Spasic’s focus on identifying and developing new opportunities to address critical problems in healthcare drives him to work at the intersection of medicine, science and business.
Prior to his current position at PICI, Dr. Spasic worked as Medical Director across PICI’s clinical trial portfolio as well as in business development with IDEAYA Biosciences, a precision oncology company in South San Francisco, helping them through their IPO as well as identifying key collaborations and partnership opportunities toward bringing new treatments closer to patients.
Dr. Spasic is also an Assistant Professor of Clinical Medicine at UCSF. His background and training include residency at UCSF, an MD from UCLA and a BA in Molecular Biology from UC Berkeley. He has received funding through HHMI, AOA and AANS, and has contributed to over 20 publications including those in Nature, Nature Medicine and Cell.
Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is radically changing the way cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the country's leading immunotherapy researchers and cancer centers, including Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.